Get the Stockscreener App
91.42
1.02%
0.84
After Hours:
91.42
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $91.42, with a volume of 2.08M.
It is up +1.02% in the last 24 hours and up +2.86% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$90.58
Open:
$91.87
24h Volume:
2.08M
Relative Volume:
1.28
Market Cap:
$45.50B
Revenue:
$9.91B
Net Income/Loss:
$1.02B
P/E Ratio:
44.60
EPS:
2.05
Net Cash Flow:
$665.00M
1W Performance:
+10.41%
1M Performance:
+2.86%
6M Performance:
-5.28%
1Y Performance:
+12.84%
1-Day Range:
$91.05
$92.26
1-Week Range:
$82.47
$92.26
52-Week Range:
$77.54
$101.10
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
91.42 | 45.50B | 9.91B | 1.02B | 665.00M | 2.05 |
|
ISRG
Intuitive Surgical Inc
|
488.27 | 175.96B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
202.04 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
RMD
Resmed Inc
|
213.97 | 31.57B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
77.80 | 15.55B | 3.90B | 392.30M | 288.10M | 1.95 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
Aniridia Treatment Market Is Going to Boom | Major Giants Alcon, Santen Pharmaceutical, Johnson & Johnson Vision - openPR.com
There's Been No Shortage Of Growth Recently For Alcon's (VTX:ALC) Returns On Capital - Yahoo Finance
Alcon lines up product launches in India, bets on rising demand for advanced eye care - MSN
Alcon: A Clear Vision, But Fully Valued (NYSE:ALC) - Seeking Alpha
GE HealthCare Hires Alcon Exec Jeannette Bankes as Patient Care Solutions CEO - Medical Product Outsourcing
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC) - Insider Monkey
Tesla, Warner Bros fend off some claims in 'Blade Runner 2049' ad dispute - Reuters
Alcon (VTX:ALC) Seems To Use Debt Quite Sensibly - simplywall.st
Alcon Scoops Up Aurion Biotech With Intent of Advancing Ophthalmology Cell Therapy AURN001 - CGTLive®
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 - Investing.com Canada
Alcon, Aurion Reach Accord in Dispute Over Public Offering - Bloomberg Law News
Bernstein raises Alcon stock price target to CHF99 from CHF97.50 By Investing.com - Investing.com South Africa
Dr. Jeffrey Martin of SightMD Becomes One of the First on Long Island to Implant the new Clareon® PanOptix® Pro Lens by Alcon - PRWeb
Alcon Publishes Agenda for 2025 Annual General Meeting - Business Wire
ALC Stock May Rise With the Introduction of PanOptix Pro in US - MSN
Alcon Introduces Clareon PanOptix Pro Intraocular Lens - Medical Product Outsourcing
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix - GuruFocus
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter - Business Wire
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals - Yahoo Finance
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space - TradingView
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 - Investing.com Canada
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 By Investing.com - Investing.com South Africa
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360 Canada
Oppenheimer Remains a Buy on Alcon (ALC) - The Globe and Mail
Stifel maintains Alcon stock Buy rating, $100 target - Investing.com
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon stock price target raised to $110 at Needham By Investing.com - Investing.com Australia
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - VisionMonday.com
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon: Innovation, Commercial Excellence, and Robust Momentum Mark Successful Capital Markets Day - Morningstar
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):